PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial

[1]  David R. Jones,et al.  A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab. , 2021, Cancer discovery.

[2]  J. Ojemann,et al.  Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis , 2021, Nature Medicine.

[3]  N. Agarwal,et al.  Immune Checkpoint Inhibitors in Prostate Cancer , 2021, Cancers.

[4]  F. Bushman,et al.  NPM–ALK-Induced Reprogramming of Mature TCR-Stimulated T Cells Results in Dedifferentiation and Malignant Transformation , 2021, Cancer Research.

[5]  P. Hegde,et al.  High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade , 2020, Nature Medicine.

[6]  Hongyu Zhao,et al.  Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors , 2020, Nature Medicine.

[7]  G. Mills,et al.  Multiplex digital spatial profiling of proteins and RNA in fixed tissue , 2020, Nature Biotechnology.

[8]  Derek W. Yecies,et al.  Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors , 2020, Nature Medicine.

[9]  C. Buchpiguel,et al.  Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings , 2020, Cancer Imaging.

[10]  Howard Y. Chang,et al.  CRISPR-engineered T cells in patients with refractory cancer , 2020, Science.

[11]  F. Bushman,et al.  CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration. , 2019, The Journal of clinical investigation.

[12]  V. Buchholz,et al.  Long-term in vivo microscopy of CAR T cell dynamics during eradication of CNS lymphoma in mice , 2019, Proceedings of the National Academy of Sciences.

[13]  M. Raffeld,et al.  Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy. , 2019, Blood advances.

[14]  M. Sadelain,et al.  Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL. , 2019, JCI insight.

[15]  D. Maloney,et al.  The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. , 2019, Blood.

[16]  H. Takematsu,et al.  GLCCI1 is a novel protector against glucocorticoid‐induced apoptosis in T cells , 2019, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[17]  C. Decaestecker,et al.  Comparing the expression profiles of steroid hormone receptors and stromal cell markers in prostate cancer at different Gleason scores , 2018, Scientific Reports.

[18]  C. June,et al.  Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[19]  Tyler J. Reich,et al.  Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells , 2018, Nature.

[20]  Hans Bitter,et al.  Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia , 2018, Nature Medicine.

[21]  Mithat Gonen,et al.  Long‐Term Follow‐up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia , 2018, The New England journal of medicine.

[22]  K. Davis,et al.  Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia , 2018, The New England journal of medicine.

[23]  Y. Zu,et al.  Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  B. Badie,et al.  Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[25]  J. Riley,et al.  Improved Expansion and In Vivo Function of Patient T Cells by a Serum-free Medium , 2017, Molecular therapy. Methods & clinical development.

[26]  Stephen J. Schuster,et al.  Chimeric Antigen Receptor T Cells in Refractory B‐Cell Lymphomas , 2017, The New England journal of medicine.

[27]  R. Levy,et al.  Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma , 2017, The New England journal of medicine.

[28]  R. Jandial,et al.  Regional Delivery of Chimeric Antigen Receptor–Engineered T Cells Effectively Targets HER2+ Breast Cancer Metastasis to the Brain , 2017, Clinical Cancer Research.

[29]  K. Mansfield,et al.  A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma , 2017, Science Translational Medicine.

[30]  M. Abolhasani,et al.  Clinical significance of endothelial cell marker CD34 and mast cell marker CD117 in prostate adenocarcinoma. , 2017, Pathology, research and practice.

[31]  R. DePinho,et al.  Effective Combinatorial Immunotherapy for Castration Resistant Prostate Cancer , 2017, Nature.

[32]  Xiuli Wang,et al.  Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. , 2016, The New England journal of medicine.

[33]  Roland Eils,et al.  Complex heatmaps reveal patterns and correlations in multidimensional genomic data , 2016, Bioinform..

[34]  S. Heimfeld,et al.  Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor–modified T cells , 2016, Science Translational Medicine.

[35]  G. Wertheim,et al.  Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia. , 2016, Cancer discovery.

[36]  J. Byrd,et al.  Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. , 2016, Blood.

[37]  M. Kortylewski,et al.  TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients , 2015, Clinical Cancer Research.

[38]  Ritsuko Nakamura,et al.  Expression and regulatory effects on cancer cell behavior of NELL1 and NELL2 in human renal cell carcinoma , 2015, Cancer science.

[39]  M. Sadelain,et al.  Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity , 2014, Science Translational Medicine.

[40]  Pamela A Shaw,et al.  Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.

[41]  B. van Steensel,et al.  Easy quantitative assessment of genome editing by sequence trace decomposition , 2014, Nucleic acids research.

[42]  Amy P Abernethy,et al.  Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). , 2014, Journal of the National Cancer Institute.

[43]  D. Bates,et al.  Fitting Linear Mixed-Effects Models Using lme4 , 2014, 1406.5823.

[44]  Frederic D. Bushman,et al.  Comparing DNA integration site clusters with scan statistics , 2014, Bioinform..

[45]  R. Foley,et al.  Immunotherapy for Prostate Cancer: Lessons from Responses to Tumor-Associated Antigens , 2014, Front. Immunol..

[46]  A. Tizzani,et al.  Circulating immunosuppressive cells of prostate cancer patients before and after radical prostatectomy: Profile comparison , 2013, International journal of urology : official journal of the Japanese Urological Association.

[47]  R. Flavell,et al.  Truncated Form of TGF-βRII, But Not Its Absence, Induces Memory CD8+ T Cell Expansion and Lymphoproliferative Disorder in Mice , 2013, The Journal of Immunology.

[48]  S. Rosenberg,et al.  Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy , 2012, Gene Therapy.

[49]  C. Klebanoff,et al.  Paths to stemness: building the ultimate antitumour T cell , 2012, Nature Reviews Cancer.

[50]  F. Bushman,et al.  Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells , 2012, Science Translational Medicine.

[51]  Anat Melamed,et al.  Estimating abundances of retroviral insertion sites from DNA fragment length data , 2012, Bioinform..

[52]  A. Bagg,et al.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.

[53]  David L. Porter,et al.  T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia , 2011, Science Translational Medicine.

[54]  Shoshannah L. Roth,et al.  A method to sequence and quantify DNA integration for monitoring outcome in gene therapy , 2011, Nucleic acids research.

[55]  U. Wetterauer,et al.  Preclinical Evaluation of a Recombinant Anti-Prostate Specific Membrane Antigen Single-Chain Immunotoxin Against Prostate Cancer , 2010, Journal of immunotherapy.

[56]  A. Dietz,et al.  Immunosuppressive CD14+HLA‐DRlow/− monocytes in prostate cancer , 2010, The Prostate.

[57]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[58]  H. Heslop,et al.  Antitumor Activity of EBV-specific T Lymphocytes Transduced With a Dominant Negative TGF-β Receptor , 2008, Journal of immunotherapy.

[59]  Zhili He,et al.  Empirical Evaluation of a New Method for Calculating Signal-to-Noise Ratio for Microarray Data Analysis , 2008, Applied and Environmental Microbiology.

[60]  Susan Halabi,et al.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  Matthias D Hofer,et al.  Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. , 2007, Human pathology.

[62]  G. Sauter,et al.  Prostate‐specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique , 2007, Histopathology.

[63]  A. Rudensky,et al.  TGFbeta signalling in control of T-cell-mediated self-reactivity. , 2007, Nature reviews. Immunology.

[64]  Sridhar Hannenhalli,et al.  Selection of Target Sites for Mobile DNA Integration in the Human Genome , 2006, PLoS Comput. Biol..

[65]  R. Flavell,et al.  Transforming growth factor-beta controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. , 2006, Immunity.

[66]  P. Alken,et al.  Expression of different vascular endothelial markers in prostate cancer and BPH tissue: an immunohistochemical and clinical evaluation. , 2004, Anticancer research.

[67]  A. Bergh,et al.  Role of transforming growth factor-beta1 in prostate cancer. , 2001, Microscopy research and technique.

[68]  W. Karpus,et al.  Down-regulation of TGF- β 1 production restores immunogenicity in prostate cancer cells , 2000, British Journal of Cancer.

[69]  R. Flavell,et al.  Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. , 2000, Immunity.

[70]  V. Reuter,et al.  Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. , 1999, Cancer research.

[71]  D. Bostwick,et al.  Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. , 1998, Urology.

[72]  Pär Stattin,et al.  Transforming growth factor β1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer , 1998 .

[73]  J. Moul,et al.  CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. , 1998, The Journal of urology.

[74]  A. Khoruts,et al.  Inflammatory cytokines enhance the in vivo clonal expansion and differentiation of antigen-activated CD4+ T cells. , 1997, Journal of immunology.

[75]  C. Cordon-Cardo,et al.  Prostate-specific membrane antigen expression in normal and malignant human tissues. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[76]  P. Schellhammer,et al.  Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. , 1996, Urology.

[77]  L. Truong,et al.  Mesenchymal-epithelial interactions and transforming growth factor-beta expression during mouse prostate morphogenesis. , 1994, Endocrinology.

[78]  M. Steiner,et al.  Transforming growth factor-beta 1 overproduction in prostate cancer: effects on growth in vivo and in vitro. , 1992, Molecular endocrinology.